Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Carolyn Revta

    TitleDirector
    SchoolUniversity of California, San Diego
    DepartmentNeurosciences
    Address9500 Gilman Drive #0949
    CA La Jolla 92093
    Phone858-246-1308
    vCardDownload vCard

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Roeland EJ, Ma JD, Nelson SH, Seibert T, Heavey S, Revta C, Gallivan A, Baracos VE. Weight loss versus muscle loss: re-evaluating inclusion criteria for future cancer cachexia interventional trials. Support Care Cancer. 2017 Feb; 25(2):365-369. PMID: 27628947.
        View in: PubMed
      2. Kronenberg DG, Hagmann CH, Ma JD, Revta C, Armstrong J, Roeland EJ. The Default Dilemma: Code Status Regardless of Medical Context. J Palliat Med. 2016 Nov; 19(11):1134. PMID: 27500355.
        View in: PubMed
      3. Ma JD, Benn M, Nelson SH, Campillo A, Heavey SF, Cramer A, Revta C, Thornberry K, Roeland EJ. Exploring the Definition of an Informed Health Care Proxy. J Palliat Med. 2016 Mar; 19(3):250-1. PMID: 26836962.
        View in: PubMed
      4. Chang A, Roeland EJ, Atayee RS, Revta C, Ma JD. Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care. J Pain Palliat Care Pharmacother. 2015 Sep; 29(3):247-60. PMID: 26368648.
        View in: PubMed
      5. Lin KJ, Ching A, Edmonds KP, Roeland EJ, Revta C, Ma JD, Atayee RS. Variable Patterns of Continuous Morphine Infusions at End of Life. J Palliat Med. 2015 Sep; 18(9):786-9. PMID: 26107143.
        View in: PubMed
      6. Bruggeman AR, Heavey SF, Ma JD, Revta C, Roeland EJ. Lack of documentation of evidence-based prognostication in cancer patients by inpatient palliative care consultants. J Palliat Med. 2015 Apr; 18(4):382-5. PMID: 25608220.
        View in: PubMed
      7. Ma JD, Heavey SF, Revta C, Roeland EJ. Novel investigational biologics for the treatment of cancer cachexia. Expert Opin Biol Ther. 2014 Aug; 14(8):1113-20. PMID: 24707881.
        View in: PubMed
      8. Corbacioglu S, Kernan N, Lehmann L, Brochstein J, Revta C, Grupp S, Martin P, Richardson PG. Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Expert Rev Hematol. 2012 Jun; 5(3):291-302. PMID: 22780209.
        View in: PubMed
      9. Cutler C, Kim HT, Ayanian S, Bradwin G, Revta C, Aldridge J, Ho V, Alyea E, Koreth J, Armand P, Soiffer R, Ritz J, Richardson PG, Antin JH. Prediction of veno-occlusive disease using biomarkers of endothelial injury. Biol Blood Marrow Transplant. 2010 Aug; 16(8):1180-5. PMID: 20184961.
        View in: PubMed
      10. Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, Martin PL, Steinbach G, Murray KF, Vogelsang GB, Chen AR, Krishnan A, Kernan NA, Avigan DE, Spitzer TR, Shulman HM, Di Salvo DN, Revta C, Warren D, Momtaz P, Bradwin G, Wei LJ, Iacobelli M, McDonald GB, Guinan EC. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant. 2010 Jul; 16(7):1005-17. PMID: 20167278.
        View in: PubMed
      11. Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, Guinan E, Vogelsang G, Krishnan A, Giralt S, Revta C, Carreau NA, Iacobelli M, Carreras E, Ruutu T, Barbui T, Antin JH, Niederwieser D. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010 Feb; 16(2):157-68. PMID: 19766729.
        View in: PubMed
      12. Richardson P, Linden E, Revta C, Ho V. Use of defibrotide in the treatment and prevention of veno-occlusive disease. Expert Rev Hematol. 2009 Aug; 2(4):365-76. PMID: 21082942.
        View in: PubMed
      13. Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, Revta C, Ebert R, Warren D, Choi S, Koreth J, Armand P, Alyea E, Carter S, Horowitz M, Antin JH, Soiffer R. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008 Dec 1; 112(12):4425-31. PMID: 18776081.
        View in: PubMed
      14. Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant. 2008 Feb; 41(3):229-37. PMID: 17994121.
        View in: PubMed
      15. Ho VT, Linden E, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide. Semin Thromb Hemost. 2007 Jun; 33(4):373-88. PMID: 17525895.
        View in: PubMed